Seedlabs

Cisplatin-DNA Adduct Immunoassay Kit for Drug Development PD

A lab kit for drug developers to measure how much a platinum-based cancer drug is damaging DNA in cells.

A research-use reagent kit - adduct-specific antisera with a plate immunoassay protocol - that lets pharma and CRO labs directly measure platinum-DNA lesion load in cells, giving cisplatin combination trials a true pharmacodynamic readout.

MedicineChemotherapy-induced organ toxicity mitigation
Metabolism and Genetic DisordersPharmaceutical R&D - pharmacodynamic biomarker kit for platinum chemotherapy combination trials

Concept

A research-use-only reagent kit: the adduct-specific rabbit antisera described in the study (two newly raised, one existing), packaged with a standardized DNA-digestion and plate immunoassay protocol, calibrators, and the in vivo adduct fingerprint as an assay-control specification. Buyers are pharma and CRO labs that need to measure whether an investigational agent actually changes platinum lesion load in cells - the natural pharmacodynamic endpoint for DNA-repair inhibitors, repair-pathway modulators, and new platinum analogs combined with cisplatin. The single wedge: convert 'platinum exposure' from a mg/m2 assumption into a measured number in preclinical and clinical samples. The demonstrated setup (fmol immunochemistry on leukocyte DNA from seven first-dose patients) defines the kit workflow; scale-up is a reagent-manufacturing and QC exercise, not new science.

Why now

The study raised and validated antisera that distinguish the individual cisDDP-DNA products and detect them at fmol sensitivity - and, critically, proved they work on real clinical material (leukocyte DNA from cancer patients after their first cisplatin dose), not just DNA treated in a tube. It supplies the first in vivo reference distribution of adduct types (65% pGpG, 22% pApG, 13% interstrand/non-adjacent, under 1% monofunctional) plus 24-hour removal kinetics, giving kit users both a QC anchor and a standard sampling timepoint. Sponsors of DNA-damage-response combinations with platinum chemotherapy currently have no off-the-shelf way to quantify lesion load in patient cells; this is that missing reagent, now shown to be derivable from the described antisera.

Written by GLM · 3 Oct 2026

AI assessment

Backed by 1 paper85

A highly focused, evidence-backed R&D tool that converts a validated lab method into a commercial reagent kit for a specific pharmaceutical niche.

Evidence strength
5/5
The idea directly translates the paper's results—specifically the use of three validated antisera on real patient leukocyte DNA—into a product without adding speculative leaps.
Market pull
4/5
Pharma and CROs have a clear, high-value need for PD biomarkers in DNA-damage-response trials, and the named beneficiaries are appropriate targets.
Novelty & moat
2/5
The idea is a commercial variant of the 'Post-Infusion Cisplatin Adduct Blood Test' already in the catalog, shifting the value prop from clinical dosing to R&D PD.
Feasibility
5/5
The science is already demonstrated in the full text; the transition to a kit is a standard manufacturing and QC process rather than a discovery challenge.
Wedge clarity
5/5
The wedge is extremely sharp: a single-purpose immunoassay kit to replace 'mg/m2 assumptions' with measured lesion load.
Simplicity / focus
5/5
The product is a single, well-defined reagent kit with a clear protocol, avoiding any 'platform' bloat.

Scored by Gemma 4 · 3 Oct 2026. Rated against a fixed rubric (evidence, market, novelty, feasibility, wedge, simplicity), relative to the closest ideas already in the catalog. A prior estimate to compare ideas before real-world signal arrives.

Persona discussion

AI personas trained on real people's expertise debate this idea as it evolves.

View the discussion →

Act on this idea

Ideas only matter if someone runs with them. Your message goes straight to the founder's inbox — nothing is stored on our servers.

Who benefits

  • Repare Therapeuticscompany

    Develops DDR-targeted precision oncology drugs; a direct adduct readout would show whether its candidates potentiate platinum lesions in patient samples.

  • Artios Pharmacompany

    DNA-repair-focused pipeline; adduct load is the natural PD endpoint for its cisplatin combination studies.

  • Charles River Laboratoriescompany

    A CRO running oncology combination studies could offer the validated adduct immunoassay as part of its biomarker services menu.

  • Tango Therapeuticscompany

    Synthetic-lethal programs frequently paired with platinum backbones; the kit enables lesion-load measurements in early trials.

  • AstraZenecacompany

    Broad DNA-damage-response portfolio often combined with platinum chemotherapy; an off-the-shelf adduct PD kit de-risks combination trial design.

Research it builds on

  1. cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: Quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
    A M Fichtinger-Schepman, A T van Oosterom, Paul H.M. Lohman et al. · 2026 · 265 citations
    All ideas from this paper →
Leave feedback
feasibility